Rossi G, Valli R, Bertolini F, Marchioni A, Cavazza A, Mucciarini C, Migaldi M, Federico M, Trentini G P, Sgambato A
Department of Pathologic Anatomy and Legal Medicine, Section of Pathologic Anatomy, University of Modena and Reggio Emilia, Modena, Italy.
Histopathology. 2005 May;46(5):522-31. doi: 10.1111/j.1365-2559.2005.02128.x.
To investigate the value of platelet-derived growth factor receptors (PDGFRs) by immunohistochemistry in discriminating KIT-negative gastrointestinal stromal tumours (GISTs) from other soft-tissue neoplasms of the digestive tract.
One-hundred and sixty-seven primary gastrointestinal mesenchymal tumours (125 GISTs, 15 intra-abdominal desmoids, 12 leiomyomas, eight leiomyosarcomas, three schwannomas, two solitary fibrous tumours, and one case each of inflammatory pseudotumour and fibroid polyp) were reclassified based on morphology and on the immunohistochemical panel recommended by the National Institutes of Health consensus on GIST. All cases were then tested with antibodies specific for PDGFR alpha and beta. Of 125 GISTs, 117 were KIT-positive (93.6%) and eight KIT-negative (6.4%). All the KIT-positive GISTs were negative for both PDGFRs, while all the eight KIT-negative GISTs expressed PDGFR-alpha, with two of them also coexpressing PDGFR-beta. Among the 42 non-GIST tumours, only a small percentage (26.6%) of desmoids immunostained for PDGFR-alpha, two of them coexpressing PDGFR-beta.
Immunostaining with PDGFR-alpha is a helpful marker in discriminating between KIT-negative GISTs and other gastrointestinal mesenchymal lesions: all KIT-negative GISTs were positive for PDFGR-alpha, while none of the other gastrointestinal mesenchymal tumours analysed, except a small subset of desmoids, was reactive with anti-PDGFRs. These preliminary data demonstrate the suitability of commercially available antibodies to detect immunohistochemically the mutually exclusive expression of KIT and PDGFR-alpha previously reported in GISTs by molecular biological techniques. Since PDGFR exists in the form of a homodimer (alphaalpha, betabeta) or heterodimer (alphabeta) and two of the KIT-negative GISTs coexpressed both PDGFR isoforms, further investigations are required to elucidate the role of PDGFR-beta in GISTs.
通过免疫组织化学研究血小板衍生生长因子受体(PDGFRs)在鉴别KIT阴性胃肠道间质瘤(GISTs)与其他消化道软组织肿瘤中的价值。
167例原发性胃肠道间叶性肿瘤(125例GISTs、15例腹腔内硬纤维瘤、12例平滑肌瘤、8例平滑肌肉瘤、3例神经鞘瘤、2例孤立性纤维瘤以及各1例炎性假瘤和纤维瘤息肉)根据形态学及美国国立卫生研究院关于GIST的共识推荐的免疫组织化学检测进行重新分类。然后用针对PDGFRα和β的特异性抗体检测所有病例。在125例GISTs中,117例KIT阳性(93.6%),8例KIT阴性(6.4%)。所有KIT阳性的GISTs两种PDGFR均为阴性,而所有8例KIT阴性的GISTs均表达PDGFR-α,其中2例同时共表达PDGFR-β。在42例非GIST肿瘤中,只有一小部分(26.6%)硬纤维瘤对PDGFR-α呈免疫染色阳性,其中2例同时共表达PDGFR-β。
PDGFR-α免疫染色是鉴别KIT阴性GISTs与其他胃肠道间叶性病变的有用标志物:所有KIT阴性GISTs对PDFGR-α均为阳性,而除一小部分硬纤维瘤外,所分析的其他胃肠道间叶性肿瘤均不与抗PDGFRs反应。这些初步数据表明市售抗体适合通过免疫组织化学检测分子生物学技术先前报道的GISTs中KIT和PDGFR-α的相互排斥表达。由于PDGFR以同二聚体(αα、ββ)或异二聚体(αβ)形式存在,且2例KIT阴性GISTs同时共表达两种PDGFR异构体,因此需要进一步研究以阐明PDGFR-β在GISTs中的作用。